Literature DB >> 28398575

Crizotinib: from discovery to accelerated development to front-line treatment.

F Blackhall, F Cappuzzo.   

Abstract

Entities:  

Year:  2018        PMID： 28398575     DOI： 10.1093/annonc/mdx121

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  2 in total

Review 1.  Targeting ALK Rearrangements in NSCLC: Current State of the Art.

Authors:  Ling Peng; Liping Zhu; Yilan Sun; Justin Stebbing; Giovanni Selvaggi; Yongchang Zhang; Zhentao Yu
Journal:  Front Oncol       Date:  2022-04-06       Impact factor: 5.738

2.  A new method for the study of biophysical and morphological parameters in 3D cell cultures: Evaluation in LoVo spheroids treated with crizotinib.

Authors:  Azzurra Sargenti; Francesco Musmeci; Carola Cavallo; Martina Mazzeschi; Simone Bonetti; Simone Pasqua; Francesco Bacchi; Giuseppe Filardo; Daniele Gazzola; Mattia Lauriola; Spartaco Santi
Journal:  PLoS One       Date:  2021-06-08       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.